{
    "Clinical Trial ID": "NCT01234402",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Ramucirumab + Capecitabine",
        "  Participants received 10 milligram per kilogram (mg/kg) Ramucirumab intravenously on day 1 of 21 days cycle along with 1000 milligram per square meter (mg/m^2) of Capecitabine twice daily orally on days 1 to 14 of 21 days cycle.",
        "INTERVENTION 2: ",
        "  Icrucumab + Capecitabine",
        "  Participants received 12 mg/kg Icrucumab intravenously on day 1 and day 8 of 21 day cycle along with 1000 mg/m^2 of Capecitabine twice daily orally on days 1 to 14 of 21 days cycle."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  The participant has histologically or cytologically confirmed breast cancer which at the time of study entry is either Stage III disease not amenable to curative therapy or Stage IV disease",
        "  Has measurable or nonmeasurable disease",
        "  Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1",
        "  Has received prior anthracycline therapy",
        "  Has received prior taxane therapy",
        "  Participants with human epidermal growth factor receptor-2 (HER2) positive disease must have progressed on or following trastuzumab",
        "  Participants with hormone receptor-positive disease must have progressed on or following hormone therapy",
        "  Has received  3 prior chemotherapy regimens in any setting (a regimen is defined as any agent[s] that has been administered for more than 1 cycle; sequential neoadjuvant/adjuvant treatment is considered 1 regimen)",
        "  Has completed any prior radiotherapy  4 weeks prior to randomization",
        "  Has completed any prior hormonal therapy  2 weeks prior to randomization",
        "  Has adverse events (AEs) that have resolved to Grade  1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v 4.0) from all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy,or hormonal therapy",
        "  Has adequate hematologic, coagulation, hepatic and renal function",
        "  Does not have:",
        "  cirrhosis at a level of Child-Pugh B (or worse) or",
        "  cirrhosis (any degree) and a history of hepatic encephalopathy or ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis",
        "  Has urinary protein is  1+ on dipstick or routine urinalysis; if urine protein  2+, a 24-hour urine collection must demonstrate < 1000 mg of protein in 24 hours to allow participation in the study",
        "  Agrees to use adequate contraception during the study period and for 12 weeks after the last dose of study medication",
        "Exclusion Criteria:",
        "  Has a concurrent active malignancy other than adequately treated nonmelanomatous skin cancer, curatively treated cervical carcinoma in situ, or other noninvasive carcinoma or in situ neoplasm. A participant with previous history of malignancy is eligible, provided that there has been a disease-free interval for > 3 years",
        "  Has a known sensitivity to capecitabine, any of its components, or other drugs formulated with polysorbate 80",
        "  Has a known sensitivity to 5-fluorouracil (5-FU)",
        "  Has a known dihydropyrimidine dehydrogenase deficiency",
        "  Has received prior capecitabine treatment for advanced breast cancer",
        "  Has received investigational therapy within 2 weeks prior to randomization",
        "  Has received bevacizumab within 4 weeks prior to randomization",
        "  Has received more than 1 prior antiangiogenic agent for breast cancer",
        "  Has a known sensitivity to agents of similar biologic composition as ramucirumab DP or Icrucumab (IMC-18F1), or other agents that specifically target vascular endothelial growth factor (VEGF)",
        "  Has an acute/subacute bowel obstruction or history of chronic diarrhea requiring ongoing medical intervention",
        "  Has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders",
        "  Has experienced a Grade  3 bleeding event within 3 months prior to randomization",
        "  Is receiving prophylactic or therapeutic anticoagulation with warfarin or any other oral anticoagulant",
        "  Has an uncontrolled intercurrent illness, including, but not limited to uncontrolled hypertension, symptomatic anemia, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorder in the opinion of the investigator",
        "  Has experienced any arterial thrombotic or thromboembolic events, including, but not limited to myocardial infarction, transient ischemic attack, or cerebrovascular accident within 6 months prior to randomization",
        "  Has brain metastases, uncontrolled spinal cord compression, or leptomeningeal disease",
        "  Has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy",
        "  Has received a prior allogeneic organ or tissue transplantation",
        "  Has undergone major surgery within 4 weeks prior to randomization, or subcutaneous venous access device placement within 7 days prior to randomization",
        "  Has had a serious nonhealing wound, ulcer, or bone fracture within 4 weeks prior to randomization",
        "  Has known HIV or AIDS infection",
        "  Has an elective or planned major surgery to be performed during the course of the trial",
        "  Participant is pregnant or lactating"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression-Free Survival (PFS)",
        "  PFS is defined as the time from the date of randomization until the date of objectively determined progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death from any cause, whichever is first. Disease progression is defined as 20% increase in the sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was the smallest on study); sum must have demonstrated an absolute increase of 5 millimeter (mm) and the appearance of 1 new lesions was progression. Participants who did not progress, were lost to follow-up, or had missed 2 or more scheduled tumor assessments were censored at the day of their last adequate tumor assessment.",
        "  Time frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 97 weeks)",
        "Results 1: ",
        "  Arm/Group Title: Ramucirumab + Capecitabine",
        "  Arm/Group Description: Participants received 10 milligram per kilogram (mg/kg) Ramucirumab intravenously on day 1 of 21 days cycle along with 1000 milligram per square meter (mg/m^2) of Capecitabine twice daily orally on days 1 to 14 of 21 days cycle.",
        "  Overall Number of Participants Analyzed: 52",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Weeks  22.1        (12.1 to 36.1)",
        "Results 2: ",
        "  Arm/Group Title: Icrucumab + Capecitabine",
        "  Arm/Group Description: Participants received 12 mg/kg Icrucumab intravenously on day 1 and day 8 of 21 day cycle along with 1000 mg/m^2 of Capecitabine twice daily orally on days 1 to 14 of 21 days cycle.",
        "  Overall Number of Participants Analyzed: 49",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Weeks  7.3        (6.3 to 13.0)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 20/52 (38.46%)",
        "  Anaemia 0/52 (0.00%)",
        "  Pancytopenia 1/52 (1.92%)",
        "  Acute myocardial infarction 0/52 (0.00%)",
        "  Atrial fibrillation 0/52 (0.00%)",
        "  Cardiac failure 1/52 (1.92%)",
        "  Cardiogenic shock 1/52 (1.92%)",
        "  Palpitations 0/52 (0.00%)",
        "  Pericardial effusion 0/52 (0.00%)",
        "  Right ventricular failure 1/52 (1.92%)",
        "  Abdominal pain 0/52 (0.00%)",
        "  Ascites 3/52 (5.77%)",
        "Adverse Events 2:",
        "  Total: 25/49 (51.02%)",
        "  Anaemia 2/49 (4.08%)",
        "  Pancytopenia 0/49 (0.00%)",
        "  Acute myocardial infarction 1/49 (2.04%)",
        "  Atrial fibrillation 1/49 (2.04%)",
        "  Cardiac failure 0/49 (0.00%)",
        "  Cardiogenic shock 0/49 (0.00%)",
        "  Palpitations 1/49 (2.04%)",
        "  Pericardial effusion 4/49 (8.16%)",
        "  Right ventricular failure 0/49 (0.00%)",
        "  Abdominal pain 1/49 (2.04%)",
        "  Ascites 0/49 (0.00%)"
    ]
}